These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15199531)

  • 1. Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
    Yardley DA
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):37-44. PubMed ID: 15199531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and taxanes as a new standard of care in breast cancer.
    Yardley DA
    Clin Breast Cancer; 2004 Jan; 4 Suppl 3():S107-12. PubMed ID: 14754467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
    Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
    Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
    Lopez M
    Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
    Metro G; Fabi A; Russillo M; Papaldo P; De Laurentiis M; Ferretti G; Pellegrini D; Nuzzo C; Graziano V; Vici P; Introna M; Felici A; Cognetti F; Carlini P
    Anticancer Res; 2008; 28(2B):1245-58. PubMed ID: 18505062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
    Heinemann V
    Oncology; 2003; 64(3):191-206. PubMed ID: 12697958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant gemcitabine therapy for breast cancer.
    Sánchez-Rovira P; Jaén A; Dueñas R; Porras I; Martínez E; Medina B; Mohedano N; Fernández M; Lozano A
    Clin Breast Cancer; 2002 May; 3 Suppl 1():39-44. PubMed ID: 12057045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant therapy with gemcitabine in breast cancer.
    Schneeweiss A; Bastert G; Huober J; Wallwiener D; Hamerla R; Lichter P
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):27-31. PubMed ID: 15685823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and docetaxel in metastatic breast cancer.
    Seidman AD
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):13-6. PubMed ID: 15685820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
    Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
    Georgoulias VA
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):18-24. PubMed ID: 11252884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
    Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):221-8. PubMed ID: 20387073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
    Halim A; Wahba H
    Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and taxanes in metastatic breast cancer.
    Amadori D; Cecconetto L
    Ann Oncol; 2006 May; 17 Suppl 5():v173-6. PubMed ID: 16807451
    [No Abstract]   [Full Text] [Related]  

  • 17. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.
    Riccardi A; Brugnatelli S; Danova M; Giordano M; Pugliese P; Luchena G; Grasso D; Trotti G; Bertè R; Pansini G; Tinelli C
    Tumori; 2006; 92(1):6-12. PubMed ID: 16683377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
    Marmé F; Aigner J; Lorenzo Bermejo J; Sinn P; Sohn C; Jäger D; Schneeweiss A
    Int J Cancer; 2013 Aug; 133(4):1006-15. PubMed ID: 23400797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
    Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
    Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of gemcitabine in breast cancer (Review).
    Silvestris N; D'Aprile M; Andreola G; Locopo N; Marini L; Crucitta E; De Lena M; Lorusso V
    Int J Oncol; 2004 Feb; 24(2):389-98. PubMed ID: 14719116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.